AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7192498
Drug: Serum antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum antibodies to cow milk proteins
Trial: 7192498
Drug: Serum antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum antibodies to soy protein
Trial: 31921170
Drug: GTU®MultiHIV DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTU®MultiHIV DNA vaccine delivered by transcutaneous (TC) and intramuscular (IM) injection
Trial: 25439415
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine 1 mg/kg
Trial: 23213984
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (n=26)
Trial: 20371164
Drug: L-alanyl-glutamine (l-Ala-Gln)
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanyl-glutamine (l-Ala-Gln)
Trial: 7719880
Drug: Bricanyl Turbuhaler
RxNorm normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bricanyl Turbuhaler (terbutaline sulphate 0.5 mg t.i.d.)
Trial: 7719880
Drug: Ventolin Rotahaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin Rotahaler (salbutamol 0.4 mg t.i.d.)
Trial: 2126657
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg after cord clamping
Trial: 7341284
Drug: Sotalol and
RxNorm normalized name: sotalol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol and Metoprolol (combined with thiazide diuretic)
Trial: 25656999
Drug: Peanut sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut sublingual immunotherapy (SLIT)
Trial: 24724774
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein as a supplement without dietary modification (WPS)
Trial: 22494623
Drug: L-BLP25
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BLP25
Trial: 19397502
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml 0.5% bupivacaine
Trial: 19397502
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml 0.25% bupivacaine
Trial: 16170977
Drug: 2.5% lidocaine/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% lidocaine/2.5% prilocaine (L/P)
Trial: 12240780
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg PO or IV q24h
Trial: 12240780
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg IV q24h for > or = 2 days plus ceftriaxone 1 g IV q24h for 2 days
Trial: 10422936
Drug: Neostigmine/glycopyrrolate (0.05/0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine/glycopyrrolate (0.05/0.01 mg/kg)
Trial: 7818126
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L unhumidified O2 via nasal cannula
Trial: 2204260
Drug: Trapidil 300
RxNorm normalized name: trapidil
DrugBank: Trapidil (DB09283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil 300 mg/day (TT group)
Trial: 23424215
Drug: Caffeine at
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine at 250 mg day(-1)
Trial: 23424215
Drug: DMAA at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMAA at 50 mg day(-1)
Trial: 23424215
Drug: Caffeine at
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine at 250 mg day(-1) + DMAA at 50 mg day(-1)
Trial: 21376643
Drug: Heparin-bonded PTFE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded PTFE grafts (Hb-PTFE)
Trial: 19304089
Drug: Topical mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mitomycin-C (MMC) 0.2 mg/mL applied for 45 seconds after PRK
Trial: 19304089
Drug: Topical mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mitomycin-C (MMC)
Trial: 17526168
Drug: Methycbal (Mecolbalamin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methycbal (Mecolbalamin) administration
Trial: 10682136
Drug: Stavudine 20
RxNorm normalized name: stavudine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 20 mg twice daily
Trial: 10682136
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg twice daily
Trial: 10682136
Drug: Stavudine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine (both doses)
Trial: 8313315
Drug: FUDR (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUDR (0.3 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day continuous infusion through an implantable hepatic arterial pump alternating with a 4‐week rest period (Group D)
Trial: 8313315
Drug: FUDR (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUDR (0.25 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day infusion alternating with 2 weeks of saline (Group E)
Trial: 8313315
Drug: FUDR (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUDR (0.3 mg/kg/day) with leucovorin (15 mg/m2/day) for 2 weeks followed by a 2‐week rest (Group F)
Trial: 8313315
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial chemotherapy with FUDR and leucovorin
Trial: 8313315
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of leucovorin (15 mg/m2) with FUDR
Trial: 3042310
Drug: BAYm 1099
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAYm 1099 (50 mg 3 times/day)
Trial: 28544774
Drug: Hetrombopag (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag (5 mg, 10 mg, 20 mg, 30 mg, 40 mg single dose)
Trial: 28544774
Drug: Hetrombopag (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag (2.5 mg, 5.0 mg, 7.5 mg once daily for 10 days)
Trial: 22004303
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (E‐TAU)
Trial: 15975966
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg subcutaneous injection, twice weekly for three months)
Trial: 12883465
Drug: Liposomal ACY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal ACY gel (LAG) applied five times daily for up to eight weeks
Trial: 12883465
Drug: Plain ACY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain ACY gel (PAG)
Trial: 10856268
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg omapatrilat
Trial: 2428668
Drug: Synchronous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronous chemotherapy
Trial: 31280100
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (IV-morphine)
Trial: 24088075
Drug: V7 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V7 (10 µg heat-killed Mycobacterium vaccae)
Trial: 14514588
Drug: Usual glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual glucose-lowering therapy
Trial: 8969731
Drug: Pause in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pause in rhGH therapy (group 1) for a mean duration of 25.5 +/- 26.9 months.
Trial: 8969731
Drug: Resumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resumption of rhGH therapy after a pause (group 2) for a mean duration of 9.0 +/- 4.6 months.
Trial: 8969731
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of rhGH therapy at the time of transplantation (30 patients).
Trial: 8969731
Drug: Post-transplantation growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation growth velocity after discontinuation of rhGH therapy.
Trial: 8969731
Drug: Delta height
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta height SDS at last follow-up after discontinuation of rhGH therapy.
Trial: 1471603
Drug: Beta-receptor antagonists
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-receptor antagonists
Trial: 7836511
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg)
Trial: 6327758
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (400 mg) at 1400 h
Trial: 6327758
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (400 mg) with dexamethasone (1 mg) at 2400 h
Trial: 21981375
Drug: CS20 protective
RxNorm normalized name: DENTAL PROTECTANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS20 protective barrier gel
Trial: 19030969
Drug: Early Gp
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Gp IIb‐IIIa inhibitors
Trial: 31376908
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (placebo or acetylsalicylic acid 100 mg daily)
Trial: 27121793
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus irinotecan (CAPIRI) therapy
Trial: 18341819
Drug: Positive autoantibodies
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive autoantibodies against AT(1)-receptor
Trial: 18341819
Drug: Negative autoantibodies
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative autoantibodies against AT(1)-receptor
Trial: 20568977
Drug: iodixanol 320
RxNorm normalized name: IODIXANOL 320mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol 320 mgI/ml
Trial: 11870488
Drug: iotrolan 300
RxNorm normalized name: Iotrolan
DrugBank: Iotrolan (DB09487)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iotrolan 300 mgI/ml
Trial: 31446510
Drug: Clinical pathway
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pathway treatment (n=17)
Trial: 27367794
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAA), arginine, and citrulline (0.17 g/kg BCAA, 0.05 g/kg arginine, 0.05 g/kg citrulline)
Trial: 26516908
Drug: Oligofructose-enriched inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oligofructose-enriched inulin (5 g)
Trial: 23238663
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (1.8 g eicosapentaenoic acid and 1.5 g docosahexaenoic acid)
Trial: 23238663
Drug: Identical olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical olive oil capsules (placebo)
Trial: 17625310
Drug: Continuous regional
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regional arterial infusion of a protease inhibitor
Trial: 1657506
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of aspirin daily in the morning
Trial: 1657506
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of aspirin four times a day
Trial: 1657506
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg four times a day)
Trial: 1657506
Drug: Enteric coating
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coating of aspirin
Trial: 27418597
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d without loading dose) plus Aspirin (300 mg loading followed by 100 mg/d)
Trial: 27418597
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg loading followed by 100 mg/d)
Trial: 23107508
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of nicotine
Trial: 19767012
Drug: Pro-constancy condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro-constancy condition (fixed biological traits)
Trial: 19767012
Drug: Anti-constancy condition
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-constancy condition (mutable biological traits)
Trial: 18386234
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg/kg IV (Group I)
Trial: 18386234
Drug: Meperidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.3 mg/kg IV followed by midazolam 0.05 mg/kg IV (Group II)
Trial: 10436098
Drug: Aspirin (antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (antiplatelet medication)
Trial: 10436098
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (control group)
Trial: 7775993
Drug: Mailed feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailed feedback on prescribing profiles and treatment recommendations for insomnia and acute cystitis
Trial: 479383
Drug: Penbutolol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol 25 to 75 mg twice daily (group A)
Trial: 479383
Drug: Penbutolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol 50 to 150 mg twice daily (group B)
Trial: 31054396
Drug: Tree thinning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tree thinning treatments
Trial: 7601015
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg or 400 mg once daily for uncomplicated urinary tract infections
Trial: 7601015
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg or 400 mg single oral dose for gonorrhoea
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for complicated urinary tract infections
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for lower respiratory tract infections
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for skin and soft tissue infections
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for pyelonephritis
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for bacterial enteritis
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for typhoid fever
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for bone and joint infections (preliminary studies)
Trial: 7601015
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg/day orally or 400 mg/day orally or intravenously
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily compared to ofloxacin 800 mg/day
Trial: 7601015
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily compared to ciprofloxacin 1000 mg/day
Trial: 7601015
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg once daily compared to norfloxacin 800 mg/day
Trial: 2253290
Drug: Mepivacaine 1.5%
RxNorm normalized name: mepivacaine 1.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 1.5% (0.35 ml.kg‐1) + norepinephrine (5 micrograms.ml‐1)
Trial: 27595693
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine U100 (IGlar)
Trial: 22948779
Drug: Activated carbon
RxNorm normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated carbon nanoparticle-epirubicin suspension
Trial: 20859315
Drug: Topical ibuprofen
RxNorm normalized name: ibuprofen Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ibuprofen (4% gel, 320 mg total, 4 times daily for 2 weeks)
Trial: 20859315
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (2400 mg total, 3 times daily for 2 weeks)
Trial: 18420964
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (22 g/d loading for 5 days; maintenance 3.76 g/d during PR)
Trial: 12651678
Drug: Lidocaine 1.5%
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5% with epinephrine 1:200,000 (3 mL)
Trial: 12651678
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline (3 mL)
Trial: 11200792
Drug: Oral lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lysine acetylsalicylate (1620 mg) combined with metoclopramide (10 mg)
Trial: 8804681
Drug: Nicotine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (20 micrograms/kg per dosing)
Trial: 8804681
Drug: Nicotine combined
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine combined with alcohol (0.5 g/kg)
Trial: 8804681
Drug: Alcohol alone
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol alone (0.5 g/kg)
Trial: 1545087
Drug: Standardized allergen
RxNorm normalized name: cat hair standardized allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized allergen extracts (100,000, 10,000, and 1000 AU/ml)
Trial: 6432415
Drug: Auranofin 3
RxNorm normalized name: auranofin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin 3 mg b.d.
Trial: 6432415
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg b.d.
Trial: 30871608
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin threshold of 9 g/dL)
Trial: 30871608
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin threshold of 7 g/dL)
Trial: 20558806
Drug: 10-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-week group intervention plus transdermal nicotine replacement
Trial: 16244488
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Trial: 16244488
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Trial: 10211174
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD)
Trial: 10211174
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release
Trial: 24423476
Drug: Dexamethasone infusion
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone infusion
Trial: 176034
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid administration
Trial: 176034
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid administration with both renin and ACTH suppression
Trial: 23714270
Drug: Economic support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Economic support (monthly voucher of ZAR120.00)